Trends in pharmacogenomics of drugs used in the treatment of asthma
Trends in pharmacogenomics of drugs used in the treatment of asthma
复制标题
DOI：
10.1016/j.phrs.2003.04.002
复制
发表时间：
2004-04-01
影响因子：
9.3
通讯作者：
Pignatti, PF
中科院分区：
文献类型：
--
作者：
Pignatti, PF
对用于治疗哮喘的药物进行的药理学研究发现，在携带与β -2激动剂或白三烯调节剂作用有关的基因中的特定基因型的患者中，反应降低的例子不多。可能会提出与这些药物相关的其他候选基因，如糖皮质激素、茶碱、抗胆碱能、抗组胺药和药物代谢酶。统计能力和人口分层可能是病例对照关联研究中重要的问题。未来的发展包括从哮喘遗传和基因组研究中扩展基因知识，开发新的预防和治疗方法，针对特定个体的药物遗传学重要基因的多种当代基因分型方法，以及哮喘功能药物基因组谱的构建。总之，哮喘药物遗传学研究似乎需要在不同人群的前瞻性临床试验中进行复制，并对大量受试者进行基因分型。建议哮喘药物实验的大型临床试验也应包括药物遗传学研究。(C) 2003 Elsevier Ltd.版权所有。
Pharmacogenetic studies of drugs used in the treatment of asthma have produced a few examples of reduced response in patients carrying specific genotypes in genes involved in the action of beta-2 agonists or leukotriene modifiers. Other candidate genes related to these drugs, as well as glucocorticoids, theophilline, anticholinergics, antihistaininics, and drug-metabolizing enzymes, may be proposed. Statistical power and population stratification may be issues of importance in case-control association studies. Future developments include expanded gene knowledge from asthma genetic and genomic studies, the development of new preventive and Curative treatments, multiple contemporary genotyping methods for pharmacogenetically important genes in a given individual, and the construction of asthma functional pharmacogenomic profiles. In conclusion, it seems that asthma pharmacogenetic studies need to be replicated in prospective clinical trials in different populations with a large number of subjects being genotyped. It is suggested that large clinical trials which are proposed for asthma drugs experimentation should include a pharmacogenetic study as well. (C) 2003 Elsevier Ltd. All rights reserved.